Premium
Clinicopathological and molecular implications of aberrant thyroid transcription factor‐1 expression in colorectal carcinomas: an immunohistochemical analysis of 1319 cases using three different antibody clones
Author(s) -
Bae Jeong Mo,
Kim Jung Ho,
Park Jeong Hwan,
Park Hye Eun,
Cho NamYun,
Kang Gyeong Hoon
Publication year - 2018
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/his.13398
Subject(s) - immunohistochemistry , clone (java method) , thyroid transcription factor 1 , pathology , colorectal cancer , kras , thyroid , biology , antibody , medicine , cancer , cancer research , adenocarcinoma , gene , immunology , genetics
Aims The precise profile of aberrant expression of thyroid transcription factor‐1 ( TTF ‐1) according to antibody clones in colorectal carcinomas ( CRC s) has been controversial. Moreover, the detailed clinicopathological and molecular features of CRC s with TTF ‐1 expression have rarely been investigated. The aim of this study was to evaluate TTF ‐1 expression status in a large series of CRC cases by using three different antibody clones. Methods and results Immunohistochemistry for TTF ‐1 with clones 8G7G3/1, SPT 24 and SP 141 was performed on tumour tissues of 1319 primary CRC s and 98 corresponding metastatic lesions. Among the 1319 CRC s, TTF ‐1 expression was detected in 68 cases by both clone SPT 24 and clone SP 141. TTF ‐1 expression was not detected in any of the cases when clone 8G7G3/1 was used. The 68 CRC s with TTF ‐1 expression detected by both clone SPT 24 and clone SP 141 were considered to be TTF ‐1‐positive in this study. TTF ‐1 positivity was significantly associated with distal tumour location, non‐mucinous histology, intact CDX 2 expression and a low frequency of KRAS mutations in CRC s. Nearly all TTF ‐1‐positive CRC s showed microsatellite‐stable and CpG island methylator phenotype‐negative statuses. TTF ‐1 positivity was also found in all metastatic lesions of the five TTF ‐1‐positive primary CRC s. TTF ‐1 negativity was maintained in all metastatic lesions of the 93 TTF ‐1‐negative primary CRC s. Conclusions Our study confirmed that the frequency and characteristics of aberrant TTF ‐1 expression in CRC s vary according to the antibody clone. Aberrant TTF ‐1 expression detected by clone SPT 24 or SP 141 may be encountered preferentially in distally located, conventional pathway‐type CRC s.